Lambert-Eaton myasthenic syndrome associated with pulmonary squamous cell carcinoma and circulating anti-P/Q-type voltage-gated calcium channel antibody
Authors:
- Tomohiko NakamuraTNTomohiko Nakamura
- Hirohisa WatanabeHWHirohisa Watanabe
- Noriyuki MatsukawaNMNoriyuki Matsukawa
- Kosei OjikaKOKosei Ojika
- Gen SobueGSGen Sobue
Open Access
- 1 January 2010
- journal article
- case report
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 50 (1) , 17-19
Abstract
症例は64歳,男性である.61歳時に肺癌のために右上葉を切除した(病理組織診断は中分化型扁平上皮癌).その約1年後に縦隔リンパ節転移をみとめ,5-FUの内服を開始した.8カ月後に左前頭部に脳転移巣がみられたが放射線治療により縮小した.5-FU内服開始1年後に易疲労感,口渇,歩行障害が出現し,下肢近位筋に優位な筋力低下,深部反射の消失,自律神経症状などの神経症状,反復刺激試験異常と抗P/Q型voltage-gated calcium channel 抗体陽性からLambert-Eaton症候群と診断した.3,4-ジアミノピリジンにより下肢筋力と歩行は著明に改善した.Keywords
This publication has 7 references indexed in Scilit:
- Distinct evolution of calcium channel antibody types in Lambert–Eaton myasthenic syndromeJournal of Neuroimmunology, 2008
- 3. Damages of Neuromuscular JunctionsNihon Naika Gakkai Zasshi, 2008
- Difficultés autour d’un syndrome de Lambert-EatonRevue des Maladies Respiratoires, 2004
- The action of Lambert–Eaton myasthenic syndrome immunoglobulin G on cloned human voltage‐gated calcium channelsMuscle & Nerve, 2002
- A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndromeNeurology, 2000
- Myasthenia gravis activities of daily living profileNeurology, 1999
- CARCINOMATOUS NEUROPATHY AND MYOPATHY A CLINICAL AND PATHOLOGICAL STUDYBrain, 1954